These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18563409)

  • 1. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).
    Durai M; Krueger C; Ye Z; Cheng L; Mackensen A; Oelke M; Schneck JP
    Cancer Immunol Immunother; 2009 Feb; 58(2):209-20. PubMed ID: 18563409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.
    Chiu YL; Schneck JP; Oelke M
    J Vis Exp; 2011 Apr; (50):. PubMed ID: 21505415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
    Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
    Meidenbauer N; Marienhagen J; Laumer M; Vogl S; Heymann J; Andreesen R; Mackensen A
    J Immunol; 2003 Feb; 170(4):2161-9. PubMed ID: 12574389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
    Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
    Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
    Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
    Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.
    Ugel S; Zoso A; De Santo C; Li Y; Marigo I; Zanovello P; Scarselli E; Cipriani B; Oelke M; Schneck JP; Bronte V
    Cancer Res; 2009 Dec; 69(24):9376-84. PubMed ID: 19934317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.
    Oelke M; Schneck JP
    Clin Immunol; 2004 Mar; 110(3):243-51. PubMed ID: 15047202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
    Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
    Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
    Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
    Front Immunol; 2021; 12():674276. PubMed ID: 34566953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.
    Mami-Chouaib F; Echchakir H; Dorothée G; Vergnon I; Chouaib S
    Immunol Rev; 2002 Oct; 188():114-21. PubMed ID: 12445285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
    Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
    J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments.
    Cochlovius B; Perschl A; Adema GJ; Zöller M
    Int J Cancer; 1999 May; 81(3):486-93. PubMed ID: 10209966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.